Hormonal
Testosterone therapy does not increase the risk of prostate cancer or benign prostatic hyperplasia (BPH) in men without existing prostate disease, but it can aggravate symptoms in men with locally advanced or metastatic prostate cancer.
Do not let the fear of prostate cancer stop you from seeking treatment for low testosterone if you are otherwise healthy. Current guidelines show no link between TRT and developing prostate cancer. However, if you already have advanced prostate cancer, TRT is contraindicated. Regular prostate checks (PSA and DRE) are essential before and during treatment.
At the present time, there is no conclusive evidence that testosterone therapy increases the risk of prostate cancer or benign prostatic hyperplasia... However, there is unequivocal evidence that testosterone can stimulate growth and aggravate symptoms in men with locally advanced and metastatic prostate cancer
Why this rating
Based on Level 4 evidence for no increased risk in general population, and Level 2a for aggravation in advanced cancer.
Source
Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations
C. Wang et al. · Journal of Andrology · 2008
DOI 10.2164/jandrol.108.006486
More from this paper
- Testosterone replacement therapy in older men with confirmed late-onset hypogonadism improves body composition by decreasing fat mass and increasing lean body mass.Limited
- Testosterone therapy improves erectile function and libido in men with documented testosterone deficiency, and may have synergistic effects when combined with phosphodiesterase-5 inhibitors in those who do not respond to either treatment alone.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →